



[CLICK TO VIEW](#)

[Table of Contents 2](#)

[List of Tables & Charts 3](#)

[Study Overview 4](#)

[Sample Text, Table & Chart 5](#)

[Sample Profile, Table & Forecast 6](#)

[Order Form 7](#)

[About Freedonia, Custom Research, Related Studies, Corporate Use License 8](#)

# Drug Delivery Systems

---

US Industry Study with Forecasts for **2012 & 2017**

---

Study #2294 | March 2008 | \$4500 | 338 pages

---

[www.freedoniagroup.com](http://www.freedoniagroup.com)



**The Freedonia Group**

767 Beta Drive

Cleveland, OH • 44143-2326 • USA

Toll Free US Tel: 800.927.5900 or +1 440.684.9600

Fax: +1 440.646.0484

E-mail: [info@freedoniagroup.com](mailto:info@freedoniagroup.com)

## Table of Contents

### EXECUTIVE SUMMARY

### MARKET ENVIRONMENT

General .....	4
Macroeconomic Trends .....	5
Demographic Patterns .....	7
Health Care Trends .....	9
Health Insurance .....	10
Medical Conditions .....	12
Acute Conditions .....	12
Chronic Conditions .....	14
National Health Expenditures .....	18
Medical Providers .....	22
Outpatient Clinics .....	23
Skilled Nursing Homes .....	24
Acute Care Hospitals .....	24
Physicians .....	25
Patient Activity .....	26
Acute Care Hospital Admissions .....	27
Surgical Procedures .....	28
Outpatient Visits .....	28
Pharmaceutical Market Overview .....	29
Regulation .....	31
Research & Development .....	31
Demand Patterns & Forecasts .....	32
Therapeutic Classes .....	33
Generic Competition .....	35
Dosage Formulations .....	37
Regulatory Classifications .....	39

### DRUG DELIVERY MATERIALS

General .....	41
Sterile & Purified Water .....	43
Synthetic Polymers .....	45
Polyethylene Glycol (PEG) .....	46
Acrylic Polymers .....	48
Carbomers .....	48
Methacrylate Copolymers .....	48
Polyethylene Oxide .....	50
Polyvinyl Alcohol .....	51
Other Synthetic Polymers .....	52
Cellulose Derivatives .....	53
Ethyl Cellulose .....	54
Hydroxypropyl Methylcellulose (HPMC) .....	55
Other Cellulose Derivatives .....	56
Minerals .....	56
Mineral Hydrocarbons .....	57
Petrolatum .....	57
Mineral Oil .....	58
Mineral Hydrocarbon Waxes .....	58
Other Minerals .....	59
Attapulgit .....	59
Calcium Carbonate .....	59
Calcium Silicate .....	60
Electrolytes .....	60
Other Drug Delivery Materials .....	61
Starch Compounds .....	62
Cyclodextrins .....	62

Dextrates .....	63
Dextrin .....	63
Maltodextrin .....	63
Sugars & Polyols .....	64
Sucrose .....	64
Sorbitol .....	65
Lactose .....	65
Mannitol .....	66
Natural Gums .....	67
All Other Drug Delivery Materials .....	67

### DRUG DELIVERY SYSTEMS OVERVIEW

General .....	69
Types of Drug Delivery Systems .....	71
Historical Demand Patterns .....	72
Regulation .....	75
Research & Development .....	76
US Trade .....	77
International Markets .....	78

### ORAL DRUG DELIVERY SYSTEMS

General .....	80
Controlled-Release Formulations .....	83
Technologies .....	85
Coated Systems .....	85
Diffusion Systems .....	88
Reservoir Systems .....	90
Chewable Tablets .....	92
Orally Disintegrating Tablets .....	95
Nanoparticulate Formulations .....	97
Ethical Pharmaceuticals .....	98
Over-the-Counter Drugs .....	101
Transmucosal Formulations .....	102

### PARENTERAL DRUG DELIVERY SYSTEMS

General .....	106
Therapeutic Monoclonal Antibodies .....	108
Technology .....	110
Anti-Cancer Agents .....	114
Other Therapeutic Monoclonal Antibodies .....	119
Products in Development .....	125
Prefilled Syringes .....	126
Applications .....	128
Injectors .....	129
Cartridges & Insulin Pens .....	131
Encapsulated Systems .....	133
Polymer-Protected Systems .....	135
PEGylated Formulations .....	135
Other Polymer-Protected Pharmaceuticals .....	139
Liposomes .....	141
Developmental Activities .....	143

Premixed IV Solutions .....	151
Mini-Bags .....	152
Bag/Vial Infusion Systems .....	153
Applications .....	154

### INHALATION, TRANSDERMAL & IMPLANTABLE DRUG DELIVERY SYSTEMS

General .....	155
Inhalation Drug Delivery Systems .....	157
Dry Powder Formulations .....	158
Devices & Technologies .....	159
Applications .....	162
Metered Dose Formulations .....	163
Devices & Technologies .....	163
Applications .....	167
Transdermal Drug Delivery Systems .....	168
Products & Technologies .....	169
Developers & Suppliers .....	171
Applications .....	173
Implantable Drug Delivery Systems .....	180
Drug-Eluting Stents .....	181
Drug Inserts .....	183
Brachytherapy .....	185

### APPLICATIONS

General .....	188
Central Nervous System Agents .....	190
Respiratory Agents .....	194
Hormones & Related Agents .....	196
Gastrointestinal Agents .....	201
Cardiovascular Agents .....	203
Anti-Infective Agents .....	207
Nutritional Agents .....	210
Biologicals .....	212
Genito-Urinary Agents .....	214
Other Therapies .....	216

### INDUSTRY STRUCTURE

General .....	220
Developmental Revenues .....	221
Market Share .....	225
Competitive Strategies .....	226
Mergers & Acquisitions .....	228
Licensing & Related Agreements .....	231
Marketing & Distribution .....	238
Manufacturing .....	239

### COMPANY PROFILES

Alkermes Incorporated .....	241
AptarGroup Incorporated .....	244
Aradigm Corporation .....	246
Associated British Foods .....	249

(continued on next page)

## Table of Contents

### COMPANY PROFILES

(continued from previous page)

Baxter International.....	251
Becton, Dickinson and Company.....	256
Catalent Pharma Solutions.....	260
Cephalon Incorporated.....	263
Consort Medical plc.....	267
Corium International.....	269
CyDex Pharmaceuticals.....	271
Depomed Incorporated.....	272
Dow Corning.....	274
DURECT Corporation.....	275
Elan Corporation.....	278
Emisphere Technologies.....	283
Eurand NV 285.....	
Flamel Technologies.....	289
Genzyme Corporation.....	292
Hospira Incorporated.....	294
Johnson & Johnson.....	298
Nastech Pharmaceutical.....	304
Nektar Therapeutics.....	307
Nitto Denko Corporation.....	312
NOF Corporation.....	314
Penwest Pharmaceuticals.....	316
ReAble Therapeutics.....	318
Safety Syringes.....	320
3M Company.....	321
Valeritas LLC.....	325
Other Companies Mentioned in Study.....	327

## List of Tables/Charts

### EXECUTIVE SUMMARY

1 Summary Table.....	3
----------------------	---

### MARKET ENVIRONMENT

1 Macroeconomic Indicators.....	7
2 Population by Age Group.....	9
3 Acute Conditions by Type.....	14
4 Chronic Conditions by Type.....	17
5 National Health Expenditures by Type.....	21
6 Medical Providers by Type.....	23
7 Patient Activity by Type.....	27
8 Pharmaceutical Demand by Therapeutic Class.....	35
9 Pharmaceutical Demand by Commercial Status.....	37
10 Pharmaceutical Demand by Dosage Formulation.....	38
11 Pharmaceutical Demand by Regulatory Classification.....	40

### DRUG DELIVERY MATERIALS

1 Drug Delivery Material Demand by Type.....	42
Cht Drug Delivery Material Demand by Type, 2007.....	43
2 Sterile & Purified Water Demand in Drug Delivery.....	45
3 Synthetic Polymer Demand in Drug Delivery.....	46
4 Cellulose Derivative Demand in Drug Delivery.....	53
5 Mineral Demand in Drug Delivery.....	57
6 Other Material Demand in Drug Delivery.....	62

### DRUG DELIVERY SYSTEMS OVERVIEW

1 Drug Delivery System Demand by Dosage Formulation.....	70
Cht Drug Delivery System Demand by Dosage Formulation, 2007.....	70
2 Drug Delivery System Demand, 1997-2007.....	75
3 US Trade in Drug Delivery Systems.....	78
4 World Drug Delivery System Demand by Region.....	79

### ORAL DRUG DELIVERY SYSTEMS

1 Oral Drug Delivery System Demand by Type.....	82
Cht Oral Drug Delivery System Demand by Type, 2007.....	82
2 Oral Controlled-Release Drug Delivery System Demand.....	84
3 Coated Controlled-Release Drug Delivery System Demand.....	88
4 Diffusion Controlled-Release Drug Delivery System Demand.....	90
5 Reservoir Controlled-Release Drug Delivery System Demand.....	92
6 Chewable Tablet Demand by Therapeutic Class.....	94
7 Orally Disintegrating Tablet Demand by Therapeutic Class.....	97
8 Nanoparticulate Oral Drug Delivery System Demand by Therapeutic Class.....	98
9 Oral Transmucosal Drug Delivery System Demand by Therapeutic Class.....	105

### PARENTERAL DRUG DELIVERY SYSTEMS

1 Parenteral Drug Delivery System Demand by Type.....	107
Cht Parenteral Drug Delivery System Demand by Type, 2007.....	108
2 Therapeutic Monoclonal Antibody Demand by Therapeutic Class.....	110

3 Therapeutic Monoclonal Antibodies Approved for US Sale.....	112
4 Prefilled Syringe Demand by Therapeutic Class.....	127
5 Encapsulated Parenteral Drug Delivery System Demand by Type & Therapeutic Class.....	134
6 Premixed IV Solution Demand by Therapeutic Class.....	152

### INHALATION, TRANSDERMAL & IMPLANTABLE DRUG DELIVERY SYSTEMS

1 Other Drug Delivery System Demand by Type.....	156
Cht Inhalation, Transdermal & Implantable Drug Delivery System Demand by Type, 2007.....	157
2 Inhalation Drug Delivery System Demand by Type & Therapeutic Class.....	158
3 Transdermal Drug Delivery System Demand by Therapeutic Class.....	169
4 Implantable Drug Delivery System Demand by Type & Therapeutic Class.....	181

### APPLICATIONS

1 Drug Delivery System Demand by Therapeutic Class.....	189
Cht Drug Delivery System Demand by Therapeutic Class, 2007.....	190
2 Central Nervous System Drug Delivery Demand by Type.....	193
3 Respiratory Drug Delivery Demand by Type.....	196
4 Hormone & Related Drug Delivery Demand by Type.....	201
5 Gastrointestinal Drug Delivery System Demand by Type.....	203
6 Cardiovascular Drug Delivery System Demand by Type.....	207
7 Anti-Infective Drug Delivery System Demand by Type.....	209
8 Nutritional Delivery System Demand by Type.....	212
9 Biological Delivery System Demand by Type.....	214
10 Genito-Urinary Drug Delivery System Demand by Type.....	216
11 Drug Delivery System Demand in Other Therapies.....	219

### INDUSTRY STRUCTURE

1 Drug Delivery Revenues by Company, 2007.....	223
Cht US Drug Delivery Product Sales by Company, 2007.....	225
2 Selected Acquisitions & Divestitures.....	230
3 Selected Cooperative Agreements.....	232

[Click here to purchase online](#)

*Growth opportunities in the US market for drug delivery systems will extend to a wide range of compounds and formulations in the oral, parenteral, inhalation and other product segments.*

## US demand to grow over 10% yearly through 2012

US demand for drug delivery systems (including the value of the delivered drugs) will increase over ten percent annually to \$132 billion in 2012. Oral drug delivery systems will continue to account for the largest share of demand through 2012 due to favorable cost advantages, a wealth of potential new product applications and significant efficacy advantages over conventional dosage formulations. Medicines adapted to controlled-release matrix, diffusion and reservoir systems will post favorable sales gains as drug makers seek to gain competitive advantages by introducing new, improved formulations of off-patent pharmaceuticals. Spurred by ingestion and onset-of-action benefits, orally disintegrating tablets and transmucosal drugs will generate strong growth opportunities in the delivery of pain control and other critical care medication. Ease of administration advantages will promote the widening use of chewable tablet dosages for nutritional, respiratory and central nervous system agents, especially pediatric preparations. Improved solubility and pharmacokinetic actions will lead to rapid growth both in the number and sales of oral nanoparticle drugs.

## Parenteral doses to be fastest growing product

Among all pharmaceutical dosage formulations, parenteral preparations will



provide the strongest growth opportunities for drug delivery systems, with demand expanding over 15 percent annually through 2012. Precise targeting advantages in the treatment of cancer and other debilitating diseases will broaden demand for therapeutic monoclonal antibodies. Extended circulation and reduced toxicity benefits will expand the range of indications served by polymer- and liposome-encapsulated drugs, especially in the areas of cancer, neurological and anti-infective therapies. Ease of administration and infection prevention advantages will boost the market for parenteral drugs and solutions sold in prefilled syringes and premixed IV systems.

An increasing incidence of chronic respiratory conditions will keep demand for inhalation drug delivery systems advancing favorably. Based on widespread use in asthma therapy, dry powder inhaler formulations will continue to record the largest share of sales. However, metered dose drugs will see slightly faster gains in demand due to ongoing improvements in particle size and propellant safety. Led by new drug-eluting stents with thinner struts and enhanced safety profiles, implantable drug delivery systems will recapture rapid growth opportunities in cardiovascular medication. Lastly, advances in electrotransport technologies will broaden applications for transdermal patches.

Copyright 2008 The Freedonia Group, Inc.

[Click here to purchase online](#)

## Sample Text, Table & Chart

### ORAL DRUG DELIVERY SYSTEMS

#### Orally Disintegrating Tablets

Orally disintegrating tablets (ODTs) are evolving into a delivery system for drugs that treat medical conditions vulnerable to sudden onset of symptoms. ODTs are used to treat allergic rhinitis, migraine headaches and schizophrenia. ODTs are used for medicines prescribed to elderly patients who have difficulty swallowing conventional dosage forms. ODTs are used for indications, demand for ODTs is expected to increase by 10 percent annually to nearly \$1 billion by 2017.

ODTs are formulated to dissolve rapidly -- usually in a matter of seconds -- in the oral cavity after placement on the tongue. Because they are taken orally without water, most drugs based on this technology incorporate excipients that mask unpleasant tastes. ODTs can be produced as compression molded tablets or lyophilized wafers. Although more expensive to manufacture than conventional dosage formulations, medicines adapted to ODT delivery systems are expected to expand significantly in number over the next decade and beyond. Pharmaceutical companies are employing these systems to introduce product line extensions eligible for patent protection and differentiable from generic versions of conventional formulations. ABILIFY (aripiprazole), RISPERDAL (risperidone) and ZYPREXA (olanzapine) for schizophrenia; ALLEGRA (fexofenadine HCl) for allergies; ARICEPT (donepezil HCl) for Alzheimer's disease; MAXALT (rizatriptan benzoate) and ZOMIG-ZMT (zolmitriptan) for migraine headaches; and ZOFRAN (ondanestron HCl) for chemotherapy-induced nausea and vomiting are among the widely prescribed drugs available in ODT dosages.

Among the available ODT technologies are Catalent Pharma Solutions' ZYDIS, CIMA LABS' DURASOLV and ORASOLV, Eurand's ADVATAB, and SPI Pharma's PHARMAFREEZE systems. Catalent's ZYDIS technology employs a proprietary freeze-drying process in which

SAMPLE  
TEXT

TABLE VII-2

### INHALATION DRUG DELIVERY SYSTEM DEMAND BY TYPE & THERAPEUTIC CLASS (million dollars)

Item	1997	2002	2007	2012	2017
Inhalation Pharm Demand (bil \$)	1.5	2.5	3.5	4.5	5.5
\$ drug delivery systems/000\$ pharm	10	15	20	25	30
Inhalation Drug Delivery Systems	1.5	2.5	3.5	4.5	5.5
By Type:					
Dry Powder	1.0	1.5	2.0	2.5	3.0
Metered Dose Liquid	0.5	1.0	1.5	2.0	2.5
By Therapeutic Class:					
Respiratory Agents	1.0	1.5	2.0	2.5	3.0
Central Nervous System Agents	0.5	1.0	1.5	2.0	2.5
Hormones & Related Agents	0.0	0.0	0.0	0.0	0.0
% inhalation	100	100	100	100	100
Other Drug Delivery System Demand	4.0	5.0	6.0	7.0	8.0

SAMPLE  
TABLE

CHART IX-1

### DELIVERY PRODUCT SALES BY COMPANY, 2007\* (\$80.2 billion)



SAMPLE  
CHART

\* sales of drugs adapted to drug delivery formulations such as controlled-release & monoclonal antibodies, as well as drugs delivered through specialized devices such as inhalers & prefilled syringes

## Sample Profile, Table & Forecast

### COMPANY PROFILES

#### Corium International Incorporated

235 Constitution Drive  
 Menlo Park, CA 94025  
 650-298-8255  
<http://www.corium.com>

Annual Sales:  
 Employment:

Key Technology:  
 delivery technology:

**SAMPLE  
PROFILE**

Corium International is a privately held company involved in the research, development and manufacture of transdermal drug delivery technologies, products and devices. The Company's technologies can be used to produce prescription transdermal drug delivery systems, over-the-counter medical treatments, wound care products, and medical devices and diagnostics.

Corium is active in the drug delivery systems industry through the development and application of the Company's proprietary CORPLEX polymer and MICROCOR mechanical microporation technologies. These systems are designed to deliver drugs across the skin and mucosa in a variety of rapid and sustained drug release profiles. Among other applications, Corium's drug delivery technologies have been used to create transdermal systems for applications such as hormone replacement, birth control, smoking cessation and motion sickness.

The Company's broad-based CORPLEX polymer platform technology can be delivered in liquid, semi-solid and solid formats for various transdermal and mucosal drug delivery applications. The CORPLEX hydrogel system consists of a composite blend of polymers

269

Copyright 2008 The Freedonia Group, Inc.

TABLE VIII-4

### HORMONE & RELATED DRUG DELIVERY DEMAND BY TYPE (million dollars)

Item	1997	2002	2007	2012	2017
Hormone & Related Demand (bil \$)	12.0	14.0	16.0	18.0	20.1
\$ DDS/000\$ hormones & related					100
Hormone & Related DDS Demand	1.0	1.5	2.0	2.5	3.0
Oral Drug Delivery Systems:					10
Controlled-Release					70
Other Oral					40
Parenteral Drug Delivery Systems:					30
Monoclonal Antibodies					100
Prefilled Syringes					10
Encapsulated Systems					30
Premixed IV Solutions					40
Other Drug Delivery Systems:					10
Inhalation					50
Transdermal					50
Implantable					100
% hormones & related agents					100
Drug Delivery Applications (bil \$)	25.0	44.0	60.2	131.0	209.0

**SAMPLE  
TABLE**

"Led by cancer indications, demand for hormones and related agents adapted to drug delivery systems will increase over 16 percent annually to nearly \$26 billion in 2012. Gains will largely reflect advances in site-specific dosage formulations based on monoclonal antibodies and, to a lesser extent, nanoparticles. Based on direct tumor-attacking actions and improved side effect profiles, monoclonal antibodies are emerging as the leading therapies for the treatment of advanced cancers."

--Section VIII, pg. 196

ONLINE: www.freedoniagroup.com

MAIL: Print out and complete the order form and send to The Freedonia Group (see address at the bottom of this form)

PHONE: Call toll free, 800.927.5900 (US) or + 1 440.684.9600

FAX: + 1 440.646.0484 (US)

EMAIL: info@freedoniagroup.com

Free Handling & Shipping

There is NO charge for handling or UPS shipping in the US. Expect delivery in 3 to 5 business days. Outside the US, Freedonia provides free airmail service. Express delivery is available at cost.

Orders Outside of the US

Checks must be made payable in US funds, drawn against a US bank and mailed directly to The Freedonia Group. For wire transfers please contact our customer service department at info@freedoniagroup.com. Credit cards accepted.

Credit Card Orders

For convenience, Freedonia accepts American Express, MasterCard or Visa. Credit card purchases must include account number, expiration date and authorized signature.

Save 15%

If you order three (3) different titles at the same time, you can receive a 15% discount. If your order is accompanied by a check or wire transfer, you may take a 5% cash discount (discounts do not apply to Corporate Use Licenses).

Corporate Use License

Now every decision maker in your organization can act on the key intelligence found in all Freedonia studies. For an additional \$2300, companies receive unlimited use of an electronic version (PDF) of the study. Place it on your intranet, e-mail it to coworkers around the world, or print it as many times as you like,

Click here to learn more about the Corporate Use License

ORDER FORM

F-WEB.2294

Drug Delivery Systems..... \$4500

Corporate Use License (add to study price) \* + \$2300

Additional Print Copies @ \$500 each \*

Total (including selected option) \$\_\_\_\_\_

Enclosed is my check (5% discount) drawn on a US bank and payable to The Freedonia Group, Inc., in US funds (Ohio residents add 7.75% sales tax)

Bill my company American Express MasterCard Visa

Credit Card #

Expiration MM YY

Signature \_\_\_\_\_

Name \_\_\_\_\_

Title \_\_\_\_\_

Company \_\_\_\_\_

Division \_\_\_\_\_

Street (No PO Box please)

City/State/Zip \_\_\_\_\_

Country \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Email \_\_\_\_\_

\* Please check appropriate option and sign below to order an electronic version of the study.

Corporate Use License Agreement

The above captioned study may be stored on the company's intranet or shared directory, available to company employees. Copies of the study may be made, but the undersigned represents that distribution of the study will be limited to employees of the company.

Signature \_\_\_\_\_

Individual Use License Agreement

The undersigned hereby represents that the above captioned study will be used by only \_\_\_ individual(s) who are employees of the company and that the study will not be loaded on a network for multiple users. In the event that usage of the study changes, the Company will promptly notify Freedonia of such change and will pay to Freedonia the appropriate fee based on Freedonia's standard fee schedule then in effect. Note: Entire company corporate use license, add \$2300; one additional user, add \$500; two additional users, add \$1000; three additional users, add \$1500.

Signature \_\_\_\_\_

**OTHER STUDIES**

**Excipients**

US excipients demand will grow 4.5% yearly through 2011. Gelatin will remain the leading compound over the intermediate term, but cellulose derivatives will eventually become the top-selling group. Other excipients expected to fare well include calcium phosphate, povidone, pregelatinized starch, petrolatum, polysorbate and natural gums. This study analyzes the \$2.3 billion excipients industry, with forecasts for 2011 and 2016 by product and application. It also evaluates market share and profiles leading players.

#2280 ..... 01/2008 ..... \$4500

**Implantable Medical Devices**

US medical implant demand will rise 9.3% yearly through 2011. Cardiac implants will remain the top-selling group, led by stents and defibrillators. Bone cement, tissue and spinal implants will pace gains in the orthopedic segment. Other fast-growing types include neurological stimulators, cochlear devices and gastric bands. This study analyzes the \$27.9 billion US medical implant industry, with forecasts for 2011 and 2016 by material and product. It also evaluates market share and profiles major players.

#2255 ..... 10/2007 ..... \$4500

**Disposable Medical Supplies**

US demand for disposable medical supplies will grow 4.9% annually through 2011. Best prospects include dry powder inhalers, prefilled syringes and transdermal patches for drug delivery; blood glucose test strips for diabetes monitoring; tissue sealants for wound closure; and daily contact lenses. This study analyzes the US disposable medical supply industry, with forecasts for 2011 and 2016 presented by product, market and raw material. It also evaluates company market share and profiles industry competitors.

#2196 ..... 05/2007 ..... \$4500

**In Vitro Diagnostics**

US demand for in vitro diagnostic (IVD) products will grow 5.1% annually through 2011. Clinical chemistry and immunoassay methods will remain the top two IVD sciences, while nucleic acid testing products will continue to generate the fastest gains. Hospital labs will stay the largest market while home health care will grow the fastest. This study analyzes the \$15.2 billion US IVD industry to 2011 and 2016 by product, application and market. It also evaluates company market share and profiles major players.

#2175 ..... 04/2007 ..... \$4500

**Nanotechnology in Health Care**

US demand for nanotechnology medical products will grow 17.5% annually through 2011, driven by the critical need for new or improved therapies and diagnostics. The greatest short-term impact will be in cancer and central nervous system disorders, followed by orthopedic nanoimplants. This study analyzes the \$23.6 billion US nanotech medical product industry to 2011, 2016 and 2021 by material, product and application. The study also reviews product development activities and profiles major players.

#2168 ..... 02/2007 ..... \$4500

**About The Freedonia Group**

The Freedonia Group, Inc., is a leading international industry market research company that provides its clients with information and analysis needed to make informed strategic decisions for their businesses. Studies help clients identify business opportunities, develop strategies, make investment decisions and evaluate opportunities and threats. Freedonia research is designed to deliver unbiased views and reliable outlooks to assist clients in making the right decisions. Freedonia capitalizes on the resources of its proprietary in-house research team of experienced economists, professional analysts, industry researchers and editorial groups. Freedonia covers a diverse group of industries throughout the United States, the emerging China market, and other world markets. Industries analyzed by Freedonia include:

- Chemicals • Plastics • Life Sciences • Packaging • Building Materials • Security & Electronics • Industrial Components & Equipment • Automotive & Transportation Equipment • Household Goods • Energy/Power Equipment

[Click here to learn more about Freedonia](#)

**Freedonia Custom Research**

Freedonia Custom Research delivers the same high quality, thorough and unbiased assessment of an industry or market as an industry study. Since the research initiative is based upon a company's specific needs, companies harness Freedonia's research capabilities and resources to answer unique questions. When you leverage the results of a Freedonia Custom Research engagement, you are able to obtain important answers to specific questions and issues associated with: mergers and acquisitions, new product launches/development, geographic expansion, entry into new markets, strategic business planning, and investment and funding decisions.

Freedonia Custom Research is ideal for companies seeking to make a strategic difference in the status quo and focus on future business growth. Working side by side with clients, Freedonia's team is able to define a research project that is custom-tailored to answer specific questions and provide the basis from which a company can make informed business decisions.

[Click here to learn more about Custom Research](#)



[Click here for complete title list](#)

[Click here to visit freedoniagroup.com](http://www.freedoniagroup.com)